A constrained funding environment and weaker Euro negatively impacted Affymetrix's gene expression array and eBioscience business units in the third quarter, causing the firm to report lower-than-expected preliminary revenues and eliciting concern from analysts and investors alike.

The Santa Clara, Calif.-based life sciences company this week said that it expects total revenue of approximately $80 million for the three months ended Sept. 30, missing an average consensus analyst expectation of $84.6 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.